Sarepta Therapeutics Inc (SRPT)
130.70
+3.31
(+2.60%)
USD |
NASDAQ |
Apr 26, 13:26
Sarepta Therapeutics Net Income (TTM): -535.98M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -535.98M |
| September 30, 2023 | -690.88M |
| June 30, 2023 | -907.68M |
| March 31, 2023 | -1.115B |
| December 31, 2022 | -703.49M |
| September 30, 2022 | -716.22M |
| June 30, 2022 | -506.63M |
| March 31, 2022 | -356.56M |
| December 31, 2021 | -418.78M |
| September 30, 2021 | -486.12M |
| June 30, 2021 | -634.47M |
| March 31, 2021 | -703.89M |
| December 31, 2020 | -554.13M |
| September 30, 2020 | -600.51M |
| June 30, 2020 | -530.34M |
| March 31, 2020 | -655.92M |
| December 31, 2019 | -715.08M |
| September 30, 2019 | -620.27M |
| June 30, 2019 | -570.33M |
| March 31, 2019 | -403.20M |
| December 31, 2018 | -361.92M |
| September 30, 2018 | -245.02M |
| June 30, 2018 | -216.36M |
| March 31, 2018 | -170.14M |
| December 31, 2017 | -50.69M |
| Date | Value |
|---|---|
| September 30, 2017 | -115.14M |
| June 30, 2017 | -124.15M |
| March 31, 2017 | -123.40M |
| December 31, 2016 | -267.26M |
| September 30, 2016 | -243.49M |
| June 30, 2016 | -238.69M |
| March 31, 2016 | -218.24M |
| December 31, 2015 | -220.03M |
| September 30, 2015 | -199.76M |
| June 30, 2015 | -177.05M |
| March 31, 2015 | -169.08M |
| December 31, 2014 | -135.79M |
| September 30, 2014 | -100.19M |
| June 30, 2014 | -113.00M |
| March 31, 2014 | -98.17M |
| December 31, 2013 | -111.98M |
| September 30, 2013 | -165.23M |
| June 30, 2013 | -172.76M |
| March 31, 2013 | -145.67M |
| December 31, 2012 | -121.29M |
| September 30, 2012 | -60.63M |
| June 30, 2012 | -15.10M |
| March 31, 2012 | -21.86M |
| December 31, 2011 | -2.318M |
| September 30, 2011 | -8.552M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-1.115B
Minimum
Mar 2023
-356.56M
Maximum
Mar 2022
-632.76M
Average
-620.27M
Median
Sep 2019
Net Income (TTM) Benchmarks
| PTC Therapeutics Inc | -626.60M |
| Vertex Pharmaceuticals Inc | 3.620B |
| Regenxbio Inc | -263.49M |
| CytomX Therapeutics Inc | -0.569M |
| Apellis Pharmaceuticals Inc | -528.63M |